Phibro Animal Health Corporation
Financials
Valuation Metrics
Phibro Animal Health Corporation's Market Cap is $1.40B. At end of 2025 it was $1.51B. Ranked #2273 of 3,121 in US market (top 73%), #912 of 1,463 on NASDAQ (top 62%), #171 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 64%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.40B | US#2,273/3,121 Sec#171/266 |
| Revenue | $1.52B | US#1,620/3,121 Sec#43/266 |
| Net Income | $100M | US#1,625/3,121 Sec#53/266 |
| Total Assets | $1.50B | US#2,263/3,121 Sec#67/266 |
| Net Assets | $385M | US#2,397/3,121 Sec#139/266 |
| Employees | 2,475 | US#1,575/3,121 Sec#37/266 |
| Value | ||
| P/E | 14.06x | US#703/3,121 Sec#19/266 |
| P/B | 3.64x | US#1,925/3,121 Sec#106/266 |
| PEG | 0.13x | US#251/3,121 Sec#11/266 |
| P/S | 0.92x | US#640/3,121 Sec#10/266 |
| EV/EBITDA | 9.00x | US#651/3,121 Sec#20/266 |
| FCF Yield | 0.70% | US#2,215/3,121 Sec#81/266 |
| Profitability | ||
| ROE | 25.87% | US#386/3,121 Sec#22/266 |
| ROA | 6.64% | US#836/3,121 Sec#46/266 |
| Op. Margin | 13.07% | US#1,349/3,121 Sec#53/266 |
| Revenue Growth | 17.12% | US#814/3,121 Sec#79/266 |
| Earnings Growth | 106.61% | US#299/3,121 Sec#13/266 |
| Financial Health | ||
| Debt Ratio | 289.45% | US#2,086/3,121 Sec#210/266 |
| Total Debt | $789M | US#1,664/3,121 Sec#49/266 |
| FCF | $10M | US#2,241/3,121 Sec#81/266 |
| Cash | $61M | US#2,494/3,121 Sec#216/266 |
| Current Ratio | 2.96x | US#814/3,121 Sec#195/266 |
| Net Debt/EBITDA | 3.08x | US#1,634/3,121 Sec#64/266 |
| Dividend | ||
| Div. Yield | 1.39% | US#1,150/3,121 Sec#20/266 |
| Div. Growth | 0.04% | US#1,259/3,121 Sec#23/266 |
| Performance | ||
| 1Y Return | -14.32% | US#2,128/3,121 Sec#203/266 |
| 1M Return | -2.48% | US#1,027/3,121 Sec#100/266 |
| From 52W High | -42.48% | US#2,529/3,121 Sec#201/266 |
| 1Y MDD | -52.13% | US#2,543/3,121 Sec#188/266 |
| Trading | ||
| Volume | 594,961 shares | US#2,620/3,121 Sec#251/266 |
| Trading Value | $21M | US#2,514/3,121 Sec#212/266 |
| Per Share | ||
| EPS | $2.46 | US#1,198/3,121 Sec#32/266 |
| BPS | $9.50 | US#1,883/3,121 Sec#75/266 |
Company Info
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.